Tapewire

Nasdaq · USD

INMB

Inmune Bio, Inc.

Export transactions ↓
Tapewire entity
7094
SEC CIK
0001711754
Parsed reports
125

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
August 09, 2019 Filed Aug 12, 2019 21:34 UTC
Tesi Raymond JosephDirector · President & CEO · 10% owner
PurchaseCommon Stock 900 $7.14 $6,428.79
Disclosure

SEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 2

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,537,933

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions.

Read SEC document
August 09, 2019 Filed Aug 12, 2019 21:34 UTC
Tesi Raymond JosephDirector · President & CEO · 10% owner
PurchaseCommon Stock 100 $7.20 $720.00
Disclosure

SEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,537,033

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.